New Zealand markets closed

Aridis Pharmaceuticals, Inc. (ARDS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.2500-0.1100 (-8.09%)
At close: 04:00PM EDT
1.3500 +0.10 (+8.00%)
After hours: 07:04PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 25.14M
Enterprise value 25.65M
Trailing P/E 2.83
Forward P/E 1.43
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)5.40
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.60

Trading information

Stock price history

Beta (5Y monthly) 0.42
52-week change 3-83.06%
S&P500 52-week change 3-8.83%
52-week high 37.7200
52-week low 30.8800
50-day moving average 31.2010
200-day moving average 32.1665

Share statistics

Avg vol (3-month) 361.97k
Avg vol (10-day) 3110.23k
Shares outstanding 517.7M
Implied shares outstanding 6N/A
Float 813.44M
% held by insiders 118.12%
% held by institutions 111.68%
Shares short (30 May 2022) 4186k
Short ratio (30 May 2022) 43.19
Short % of float (30 May 2022) 41.14%
Short % of shares outstanding (30 May 2022) 41.05%
Shares short (prior month 28 Apr 2022) 4109.45k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,588.39%

Management effectiveness

Return on assets (ttm)-130.59%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)2.72M
Revenue per share (ttm)0.19
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)-35.4M
EBITDA -42.76M
Net income avi to common (ttm)-46.21M
Diluted EPS (ttm)-3.2630
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)12.47M
Total cash per share (mrq)0.7
Total debt (mrq)12.99M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.64
Book value per share (mrq)-1.15

Cash flow statement

Operating cash flow (ttm)-29.09M
Levered free cash flow (ttm)-20.93M